EP1165084A4 - PRENYL PROTEIN TRANSFERASES INHIBITORS - Google Patents

PRENYL PROTEIN TRANSFERASES INHIBITORS

Info

Publication number
EP1165084A4
EP1165084A4 EP00910386A EP00910386A EP1165084A4 EP 1165084 A4 EP1165084 A4 EP 1165084A4 EP 00910386 A EP00910386 A EP 00910386A EP 00910386 A EP00910386 A EP 00910386A EP 1165084 A4 EP1165084 A4 EP 1165084A4
Authority
EP
European Patent Office
Prior art keywords
prenyl protein
protein transferases
inhibitors
transferases inhibitors
prenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00910386A
Other languages
German (de)
French (fr)
Other versions
EP1165084A1 (en
Inventor
Craig A Stump
Theresa M Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1165084A1 publication Critical patent/EP1165084A1/en
Publication of EP1165084A4 publication Critical patent/EP1165084A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP00910386A 1999-03-03 2000-03-01 PRENYL PROTEIN TRANSFERASES INHIBITORS Withdrawn EP1165084A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12297199P 1999-03-03 1999-03-03
US122971P 1999-03-03
US12725299P 1999-03-31 1999-03-31
US127252P 1999-03-31
PCT/US2000/005354 WO2000051614A1 (en) 1999-03-03 2000-03-01 Inhibitors of prenyl-protein transferases

Publications (2)

Publication Number Publication Date
EP1165084A1 EP1165084A1 (en) 2002-01-02
EP1165084A4 true EP1165084A4 (en) 2002-05-15

Family

ID=26821069

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00910386A Withdrawn EP1165084A4 (en) 1999-03-03 2000-03-01 PRENYL PROTEIN TRANSFERASES INHIBITORS

Country Status (5)

Country Link
EP (1) EP1165084A4 (en)
JP (1) JP2002538121A (en)
AU (1) AU3248600A (en)
CA (1) CA2362495A1 (en)
WO (1) WO2000051614A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10035927A1 (en) 2000-07-21 2002-03-07 Asta Medica Ag New heteroaryl derivatives and their use as medicines
DE10035928A1 (en) 2000-07-21 2002-03-07 Asta Medica Ag New heteroaryl derivatives and their use as medicines
UA79286C2 (en) * 2002-06-29 2007-06-11 Zentaris Gmbh Arylcarbonylpipererazines and heteroarylcarbonylpiperazines and their use in the treatment of benign and malignant tumors
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
JP2010502664A (en) 2006-09-11 2010-01-28 ノバルティス アクチエンゲゼルシャフト Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
KR20150036210A (en) 2007-06-13 2015-04-07 인사이트 코포레이션 Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
AR076794A1 (en) 2009-05-22 2011-07-06 Incyte Corp DERIVATIVES OF N- (HETERO) ARIL-PIRROLIDINA DE PIRAZOL-4-IL-PIRROLO [2,3-D] PIRIMIDINES AND PIRROL-3-IL-PIRROLO [2,3-D] PYRIMIDINS AS INHIBITORS OF THE JANUS KINASE AND COMPOSITIONS PHARMACEUTICS THAT CONTAIN THEM
SI2432472T1 (en) 2009-05-22 2019-11-29 Incyte Holdings Corp 3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)octane- or heptane-nitrile as jak inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011103091A1 (en) 2010-02-18 2011-08-25 Transtech Pharma, Inc. Phenyl-heteroaryl derivatives and methods of use thereof
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
PE20130216A1 (en) 2010-05-21 2013-02-27 Incyte Corp TOPICAL FORMULATION FOR A JAK INHIBITOR
WO2011153359A1 (en) 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
PE20140146A1 (en) 2010-11-19 2014-02-06 Incyte Corp PYRROLOPYRIDINE DERIVATIVES AND PYRROLOPYRIMIDINE SUBSTITUTED WITH CYCLOBUTYL AS JAK INHIBITORS
CN103797010B (en) 2011-06-20 2016-02-24 因塞特控股公司 As the azetidinyl phenyl of JAK inhibitor, pyridyl or pyrazinyl carboxamides derivatives
US8921533B2 (en) 2011-07-25 2014-12-30 Chromatin Technologies Glycosylated valproic acid analogs and uses thereof
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
TW201406761A (en) 2012-05-18 2014-02-16 Incyte Corp Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
PH12020551186B1 (en) 2012-11-15 2024-03-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
RS62867B1 (en) 2013-03-06 2022-02-28 Incyte Holdings Corp Processes and intermediates for making a jak inhibitor
SMT202000315T1 (en) 2013-08-07 2020-07-08 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
WO2015070367A1 (en) * 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Piperidine or piperazine linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US10196383B2 (en) 2015-07-17 2019-02-05 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
KR20200066690A (en) 2017-10-16 2020-06-10 칭화대학교 Mevalonate pathway inhibitors and pharmaceutical compositions thereof
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
SG11202007164UA (en) 2018-01-30 2020-08-28 Incyte Corp Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
SMT202400306T1 (en) 2018-03-30 2024-09-16 Incyte Corp Treatment of hidradenitis suppurativa using jak inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093726A (en) * 1976-12-02 1978-06-06 Abbott Laboratories N-(2-benzimidazolyl)-piperazines
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
JPS63183565A (en) * 1986-09-24 1988-07-28 Ss Pharmaceut Co Ltd Imidazole derivative
JPH01132579A (en) * 1987-11-19 1989-05-25 Ss Pharmaceut Co Ltd Indole derivative
US4940793A (en) * 1984-08-14 1990-07-10 Ravizza S.P.A. Pharmacologically active piperazino derivatives
EP0463756A1 (en) * 1990-06-20 1992-01-02 Pfizer Limited Pyrazolopyrimidinone antianginal agents
US5306719A (en) * 1986-07-31 1994-04-26 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106663A (en) * 1980-12-23 1982-07-02 Kyorin Pharmaceut Co Ltd 1,4-disubstituted piperazine derivative and its preparation
US5856326A (en) * 1995-03-29 1999-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093726A (en) * 1976-12-02 1978-06-06 Abbott Laboratories N-(2-benzimidazolyl)-piperazines
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
US4940793A (en) * 1984-08-14 1990-07-10 Ravizza S.P.A. Pharmacologically active piperazino derivatives
US5306719A (en) * 1986-07-31 1994-04-26 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof
JPS63183565A (en) * 1986-09-24 1988-07-28 Ss Pharmaceut Co Ltd Imidazole derivative
JPH01132579A (en) * 1987-11-19 1989-05-25 Ss Pharmaceut Co Ltd Indole derivative
EP0463756A1 (en) * 1990-06-20 1992-01-02 Pfizer Limited Pyrazolopyrimidinone antianginal agents

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
BOOTH ET AL., J. AM. CHEM. SOC., vol. 119, no. 21, 1997, pages 4882 - 4886 *
CURTIN M L ET AL: "Discovery an Evaluation of a Series of 3-Acylindole Imidazopyridine Platelet-Activating Factor Antagonists", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 41, no. 1, 1998, pages 74 - 95, XP002109994, ISSN: 0022-2623 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002193469, Database accession no. 6443926,6446913,6447198,6447609,6448837,6453688 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002193470, Database accession no. 5967252,5979619 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002193471, Database accession no. 5470544,5471348,5486918,5487504 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002193472, Database accession no. 562408,575956 *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002193473, Database accession no. 7775462 *
DUBEY ET AL., J. MED. CHEM., vol. 28, no. 11, 1985, pages 1748 - 1750 *
ELLINGBOE ET AL., J. MED. CHEM., vol. 35, no. 4, 1992, pages 705 - 716 *
GHOSH ET AL., INDIAN J. CHEM., vol. 1, 1963, pages 528- - 529 *
KLIOZE ET AL., J. MED. CHEM., vol. 23, no. 6, 1980, pages 677 - 679 *
PATENT ABSTRACTS OF JAPAN vol. 012, no. 462 (C - 549) 5 December 1988 (1988-12-05) *
PATENT ABSTRACTS OF JAPAN vol. 013, no. 384 (C - 629) 24 August 1989 (1989-08-24) *
See also references of WO0051614A1 *

Also Published As

Publication number Publication date
EP1165084A1 (en) 2002-01-02
CA2362495A1 (en) 2000-09-08
JP2002538121A (en) 2002-11-12
WO2000051614A1 (en) 2000-09-08
AU3248600A (en) 2000-09-21

Similar Documents

Publication Publication Date Title
EP1165084A4 (en) PRENYL PROTEIN TRANSFERASES INHIBITORS
EP1165082A4 (en) PRENYLE PROTEIN TRANSFERASE INHIBITORS
EP1324985A4 (en) PRENYL PROTEIN TRANSFERASE INHIBITORS
PT1181017E (en) METALOPROTEASE INHIBITORS
ID30460A (en) INHIBITORS, INHIBITORS, THYROCIN CINASE PROTEIN
EP0891350A4 (en) FARNESYLE PROTEIN TRANSFERASE INHIBITORS
PT1226136E (en) TIROSIN KINASE INHIBITORS
DE50015294D1 (en) microtome
EP0986384A4 (en) ISOPRENYL TRANSFERASE PROTEIN INHIBITORS
EP1226138A4 (en) FAB I INHIBITORS
PT1194404E (en) ASPARTIL-PROTEASE INHIBITORS
PT1224195E (en) TGLS2 INHIBITOR C-ARYL-GLYCOSIDES
DE69924876D1 (en) FARNESYL PROTEIN TRANSFERASE INHIBITORS
DK1218383T3 (en) Biocyclic imidazo-5-yl amino derivatives
EP0904080A4 (en) FARNESYLE PROTEIN TRANSFERASE INHIBITORS
EP1158982A4 (en) PRENYLE PROTEIN TRANSFERASE INHIBITORS
ATE252547T1 (en) MATRIXMETALLOPROTEINASE INHIBITORS
DE60024101D1 (en) ENZYME INHIBITORS
EP0891353A4 (en) FARNESYLE PROTEIN TRANSFERASE INHIBITORS
DE60024023D1 (en) Phaser
DE60009260D1 (en) THIOPYRANDERIVATE AS MMP INHIBITORS
ATE295417T1 (en) ANGIOSTATIN-BINDING PROTEIN
EP1158983A4 (en) PRENYL PROTEIN TRANSFERASES INHIBITORS
EP1165013A4 (en) PRENYL PROTEIN TRANSFERASE INHIBITORS
DE60030066D1 (en) tester

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011004

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20011004;LT PAYMENT 20011004;LV PAYMENT 20011004;MK PAYMENT 20011004;RO PAYMENT 20011004;SI PAYMENT 20011004

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 401/12 A, 7C 07D 233/54 B, 7C 07D 403/12 B, 7C 07D 405/12 B, 7A 61K 31/4164 B, 7A 61P 35/00 B

A4 Supplementary search report drawn up and despatched

Effective date: 20020404

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20021001